Sodelglitazar

Sodelglitazar, formerly known as GW 677954, is a thiazole PPARδ receptor agonist developed by GlaxoSmithKline.^[1] While it is primarily active at the PPARδ receptor, it is considered a pan agonist with activity at PPARα and PPARγ receptors.^[2]

Safety

Phase 2 studies were terminated prior to completion due to safety findings in rodent studies.^[3]

See also

• GW501516
• GFT505
• MBX-8025
• GW0742
• Peroxisome proliferator-activated receptor

References

3. "A randomised,double-blind, parallel group, placebo-controlled, multicentre study to evaluate the safety, tolerability and efficacy of oral GW677954 capsules 2.5mg, 5mg, 10mg and 20mg a day for 24 weeks in overweight dyslipidaemic subjects" (PDF). GlaxoSmithKline. 2013-09-01.